Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: A southwest oncology group study-Reference-Cited by-同舟云学术

Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: A southwest oncology group study

Published:1995-03 Issue:1 Volume:13 Page:67-71
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Williamson Stephen K.,Crowley John J.,Livingston Robert B.,Panella Timothy J.,Goodwin John Wendall

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/BF02614223.pdf

Reference15 articles.

1. Silverberg E, Lubera JA: Cancer Statistics, 1989. Ca-A Cancer Journal for Clinicians 39: 3–21, 1989

2. Minna JD, Higgins GA, Glatstien EJ: Cancer of the lung. In: DeVita VT Jr, Hellman S, Rosenberg SA: Cancer Principles and Practice of Oncology, J.B. Lippincott Company, Philadelphia, pp. 507–597, 1985

3. Hoffman PC, Bitran JD, Golomb HD: Chemotherapy of metastatic non-small cell bronchogenic carcinoma. Seminars in Oncology 10:111–122, 1983

4. Klastersky J, Sculier JP: Chemotherapy of non-small cell lung cancer. Seminars in Oncology 12: 38–49, 1985 (suppl. 6)

5. Clinical Brochure: Fazarabine (Ara-AC), NSC-281272, DCT, National Cancer Institute, Bethesda, MD, March 1991

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pyrimidine-based anticancer drugs;New Strategies Targeting Cancer Metabolism;2022

2. Chromatin dynamics at the core of kidney fibrosis;Matrix Biology;2018-08

3. Lung cancer epigenetics: From knowledge to applications;Seminars in Cancer Biology;2018-08

4. Nucleosidic DNA demethylating epigenetic drugs – A comprehensive review from discovery to clinic;Pharmacology & Therapeutics;2018-08

5. Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies;Current Cancer Drug Targets;2016-10-17